Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.42 |
| ▸ | JAK1 | P23458 | 12/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 9/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228627 | 0.88 | JAK1 (0.48) | JAK2JAK1L3MBTL1HTR6 | |
| SCHEMBL10227678 | 0.88 | JAK1 (0.48) | JAK2JAK1L3MBTL1HTR6 | |
| SCHEMBL17711603 | 0.86 | JAK3 (0.39) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL17545881 | 0.84 | JAK1 (0.47) | JAK2JAK1L3MBTL1JAK3HTR6 | |
| SCHEMBL10227681 | 0.83 | JAK1 (0.48) | JAK2JAK1L3MBTL1JAK3HTR6 | |
| SCHEMBL17545962 | 0.83 | JAK1 (0.46) | JAK2JAK1L3MBTL1JAK3HTR6 | |
| SCHEMBL12148936 | 0.81 | JAK3 (0.42) | JAK2JAK1L3MBTL1JAK3HTR6 | |
| SCHEMBL28416778 | 0.81 | JAK1 (0.42) | JAK2JAK1L3MBTL1JAK3ATR | |
| SCHEMBL29712023 | 0.80 | JAK1 (0.48) | JAK2JAK1L3MBTL1JAK3TYK2 | |
| SCHEMBL2731818 | 0.80 | JAK2 (0.43) | JAK2JAK1L3MBTL1JAK3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685515-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114644636-A | Method for preparing tofacitinib key intermediate | 江苏恒沛药物科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-2531508-A1 | PYRROLO [ 2, 3 - D]PYRIMIDINE UREA COMPOUNDS AS JAK INHIBITORS | Pfizer Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120309776-A1 | PYRROLO[2,3-D]PYRIMIDINE UREA COMPOUNDS AS JAK INHIBITORS | PFITZER INC. | 2012-12-06 | — | — | US | disclosed |
| WO-2011097087-A1 | PYRROLO [ 2, 3 - D] PYRIMIDINE UREA COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309776-A1 | PYRROLO[2,3-D]PYRIMIDINE UREA COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885L3MBTL1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.